Aberrant expression of mucin core proteins and O-linked glycans associated with progression of pancreatic cancer

Clinical Cancer Research

Volumn 19, Issue 8, 2013, Pages 1981-1993

  Remmers, Neeley ^a,b   Anderson, Judy M ^b   Linde, Erin M ^a   DiMaio, Dominick J ^a   Lazenby, Audrey J ^a   Wandall, Hans H ^c   Mandel, Ulla ^c,d   Clausen, Henrik ^c   Yu, Fang ^b   Hollingsworth, Michael A ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c University of Copenhagen ^*  (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CORE PROTEIN; GLYCAN DERIVATIVE; LEWIS X ANTIGEN; MUCIN; MUCIN 1; MUCIN 16; MUCIN 17; MUCIN 2; MUCIN 4; MUCIN 5AC; MUCIN 5B; MUCIN 6; MUCIN 7; O LINKED GLYCAN; SIALYL LEWIS C ANTIGEN; SIALYL LEWIS X ANTIGEN; STN ANTIGEN; T ANTIGEN; TN ANTIGEN; TN STN ON MUCIN 1 ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ACINAR CELL CARCINOMA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; AUTOPSY; CANCER GROWTH; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; METAPLASIA; PANCREAS ADENOCARCINOMA; PANCREAS ADENOMA; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; TUMOR INVASION; TUMOR MICROENVIRONMENT;

ACINAR CELLS; ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTIGENS, VIRAL, TUMOR; AUTOPSY; DISEASE PROGRESSION; FEMALE; GLYCOSYLATION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUCIN-1; MUCIN-4; MUCIN-6; MUCINS; OLIGOSACCHARIDES; PANCREATIC NEOPLASMS; POLYSACCHARIDES; PROTEIN ISOFORMS;

EID: 84877096549     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2662     Document Type: Article

References (65)

1. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004;4:45-60. (Pubitemid 38082153)
2. Bafna S, Kaur S, Batra SK. Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene 2010;29:2893-904.
3. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. R Stat Soc 1995;57:289-300.
4. Tarp MA, Clausen H. Mucin-type O-glycosylation and its potential use in drug and vaccine development. Biochim Biophys Acta 2008;1780:546-63.
5. Kim GE, Bae HI, Park HU, Kuan SF, Crawley SC, Ho JJ, et al. Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas. Gastroenterology 2002;123:1052-60.
6. Schuessler MH, Pintado S, Welt S, Real FX, Xu M, Melamed MR, et al. Blood group and blood-group-related antigens in normal pancreas and pancreas cancer: enhanced expression of precursor type 1, Tn and sialyl-Tn in pancreas cancer. Int J Cancer 1991;47:180-7.
7. Lan MS, Finn OJ, Fernsten PD, Metzgar RS. Isolation and properties of a human pancreatic adenocarcinoma-associated antigen, DU-PAN-2. Cancer Res 1985;45:305-10. (Pubitemid 15196972)
8. Giorgadze TA, Peterman H, Baloch ZW, Furth EE, Pasha T, Shiina N, et al. Diagnostic utility of mucin profile in fine-needle aspiration specimens of the pancreas: an immunohistochemical study with surgical pathology correlation. Cancer 2006;108:186-97.
9. Nakajima K, Ota H, Zhang MX, Sano K, Honda T, Ishii K, et al. Expression of gastric gland mucous cell-type mucin in normal and neoplastic human tissues. J Histochem Cytochem 2003;51:1689-98. (Pubitemid 37475442)
10. Ho JJ, Kim YS. Serological pancreatic tumor markers and the MUC1 apomucin. Pancreas 1994;9:674-91. (Pubitemid 24317817)
11. Swartz MJ, Batra SK, Varshney GC, Hollingsworth MA, Yeo CJ, Cameron JL, et al. MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Am J Clin Pathol 2002;117:791-6. (Pubitemid 34457016)
12. Jhala N, Jhala D, Vickers SM, Eltoum I, Batra SK, Manne U, et al. Biomarkers in diagnosis of pancreatic carcinoma in fine-needle aspirates. Am J Clin Pathol 2006;126:572-9.
13. Ju T, Lanneau GS, Gautam T, Wang Y, Xia B, Stowell SR, et al. Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc. Cancer Res 2008;68:1636-46. (Pubitemid 351416547)
14. Qin W, Zhong X, Fan JM, Liu XR, Li Z, Ma XY. [Effect of methylation modification on the expression of Cosmc gene in peripheral B lymphocyte of IgA nephropathy patients]. Sichuan Da Xue Xue Bao Yi Xue Ban 2011;42:762-5.
15. Rooman I, Real FX. Pancreatic ductal adenocarcinoma and acinar cells: a matter of differentiation and development? Gut 2012;61:449-58.
16. Rose MC, Voynow JA. Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol Rev 2006;86:245-78.
17. Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 2009;9:874-85.
18. Lee G, Ge B, Huang TK, Zheng G, Duan J, Wang IH. Positive identification of CA215 pan cancer biomarker from serum specimens of cancer patients. Cancer Biomark 2010;6:111-7.
19. Haridas D, Chakraborty S, Ponnusamy MP, Lakshmanan I, Rachagani S, Cruz E, et al. Pathobiological implications of MUC16 expression in pancreatic cancer. PLoS ONE 2011;6:e26839.
20. Bennett EP, Mandel U, Clausen H, Gerken TA, Fritz TA, Tabak LA. Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family. Glycobiology 2012;22:736-56.
21. Zhao Q, Guo X, Nash GB, Stone PC, Hilkens J, Rhodes JM, et al. Circulating galectin-3 promotes metastasis by modifying MUC1 localization on cancer cell surface. Cancer Res 2009;69:6799-806.
22. Swanson BJ, McDermott KM, Singh PK, Eggers JP, Crocker PR, Hollingsworth MA. MUC1 is a counter-receptor for myelin-associated glycoprotein (Siglec-4a) and their interaction contributes to adhesion in pancreatic cancer perineural invasion. Cancer Res 2007;67:10222-9. (Pubitemid 350070795)
23. Belisle JA, Horibata S, Jennifer GA, Petrie S, Kapur A, Andre S, et al. Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes. Mol Cancer 2010;9:118.
24. Brinkman-Van der Linden EC, Varki A. New aspects of siglec binding specificities, including the significance of fucosylation and of the sialyl-Tn epitope. Sialic acid-binding immunoglobulin superfamily lectins. J Biol Chem 2000;275:8625-32. (Pubitemid 30180212)
25. Singh M, Maitra A. Precursor lesions of pancreatic cancer: molecular pathology and clinical implications. Pancreatology 2007;7:9-19. (Pubitemid 46725717)
26. Behrens ME, Grandgenett PM, Bailey JM, Singh PK, Yi CH, Yu F, et al. The reactive tumor microenvironment: MUC1 signaling directly reprograms transcription of CTGF. Oncogene 2010;29:5667-77.
27. Ye Q, Yan Z, Liao X, Li Y, Yang J, Sun J, et al. MUC1 induces metastasis in esophageal squamous cell carcinoma by upregulating matrix metalloproteinase 13. Lab Invest 2011;91:778-87.
28. Roy LD, Sahraei M, Subramani DB, Besmer D, Nath S, Tinder TL, et al. MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene 2011;30:1449-59.
29. Wen Y, Caffrey TC, Wheelock MJ, Johnson KR, Hollingsworth MA. Nuclear association of the cytoplasmic tail of MUC1 and beta-catenin. J Biol Chem 2003;278:38029-39. (Pubitemid 37175334)
30. Wei X, Xu H, Kufe D. Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell 2005;7:167-78. (Pubitemid 40248342)
31. Singh PK, Behrens ME, Eggers JP, Cerny RL, Bailey JM, Shanmugam K, et al. Phosphorylation of MUC1 by Met modulates interaction with p53 and MMP1 expression. J Biol Chem 2008;283:26985-95.
32. Wei X, Xu H, Kufe D. Human mucin 1 oncoprotein represses transcription of the p53 tumor suppressor gene. Cancer Res 2007;67:1853-8. (Pubitemid 46383412)
33. Raina D, Ahmad R, Chen D, Kumar S, Kharbanda S, Kufe D. MUC1 oncoprotein suppresses activation of the ARF-MDM2-p53 pathway. Cancer Biol Ther 2008;7:1959-67.
34. Raina D, Kharbanda S, Kufe D. The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts. J Biol Chem 2004;279:20607-12. (Pubitemid 38656454)
35. Carraway KL III, Funes M, Workman HC, Sweeney C. Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways. Curr Top Dev Biol 2007;78:1-22.
36. Ramsauer VP, Pino V, Farooq A, Carothers Carraway CA, Salas PJ, Carraway KL. Muc4-ErbB2 complex formation and signaling in polarized CACO-2 epithelial cells indicate that Muc4 acts as an unorthodox ligand for ErbB2. Mol Biol Cell 2006;17:2931-41. (Pubitemid 43993498)
37. Chaturvedi P, Singh AP, Moniaux N, Senapati S, Chakraborty S, Meza JL, et al. MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins. Mol Cancer Res 2007;5:309-20. (Pubitemid 46706993)
38. Moniaux N, Chaturvedi P, Varshney GC, Meza JL, Rodriguez-Sierra JF, Aubert JP, et al. Human MUC4 mucin induces ultra-structural changes and tumorigenicity in pancreatic cancer cells. Br J Cancer 2007;97:345-57. (Pubitemid 47196741)
39. Ponnusamy MP, Lakshmanan I, Jain M, Das S, Chakraborty S, Dey P, et al. MUC4 mucin-induced epithelial to mesenchymal transition: a novel mechanism for metastasis of human ovarian cancer cells. Oncogene 2010;29:5741-54.
40. Lakshmanan I, Ponnusamy MP, Das S, Chakraborty S, Haridas D, Mukhopadhyay P, et al. MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells. Oncogene 2012;31:805-17.
41. Comamala M, Pinard M, Theriault C, Matte I, Albert A, Boivin M, et al. Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells. Br J Cancer 2011;104:989-99.
42. Theriault C, Pinard M, Comamala M, Migneault M, Beaudin J, Matte I, et al. MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis. Gynecol Oncol 2011;121:434-43.
43. Reid CJ, Hyde K, Ho SB, Harris A. Cystic fibrosis of the pancreas: involvement of MUC6 mucin in obstruction of pancreatic ducts. Mol Med 1997;3:403-11. (Pubitemid 27353619)
44. Yue T, Goldstein IJ, Hollingsworth MA, Kaul K, Brand RE, Haab BB. The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays. Mol Cell Proteomics 2009;8:1697-707.
45. Chen S, LaRoche T, Hamelinck D, Bergsma D, Brenner D, Simeone D, et al. Multiplexed analysis of glycan variation on native proteins captured by antibody microarrays. Nat Methods 2007;4:437-44. (Pubitemid 46901278)
46. Yue T, Partyka K, Maupin KA, Hurley M, Andrews P, Kaul K, et al. Identification of blood-protein carriers of the CA 19-9 antigen and characterization of prevalence in pancreatic diseases. Proteomics 2011;11:3665-74.
47. Pedersen JW, Blixt O, Bennett EP, Tarp MA, Dar I, Mandel U, et al. Seromic profiling of colorectal cancer patients with novel glycopeptide microarray. Int J Cancer 2011;128:1860-71.
48. Freire T, Lo-Man R, Bay S, Leclerc C. Tn glycosylation of the MUC6 protein modulates its immunogenicity and promotes the induction of Th17-biased T cell responses. J Biol Chem 2011;286:7797-811.
49. Li S, Intini G, Bobek LA. Modulation of MUC7 mucin expression by exogenous factors in airway cells in vitro and in vivo. Am J Respir Cell Mol Biol 2006;35:95-102. (Pubitemid 43993158)
50. Mejias-Luque R, Linden SK, Garrido M, Tye H, Najdovska M, Jenkins BJ, et al. Inflammation modulates the expression of the intestinal mucins MUC2 and MUC4 in gastric tumors. Oncogene 2010;29:1753-62.
51. Turner J, Jones CE. Regulation of mucin expression in respiratory diseases. Biochem Soc Trans 2009;37(Pt 4):877-81.
52. Voynow JA, Gendler SJ, Rose MC. Regulation of mucin genes in chronic inflammatory airway diseases. Am J Respir Cell Mol Biol 2006;34:661-5. (Pubitemid 43825329)
53. Moniaux N, Varshney GC, Chauhan SC, Copin MC, Jain M, Wittel UA, et al. Generation and characterization of anti-MUC4 monoclonal antibodies reactive with normal and cancer cells in humans. J Histochem Cytochem 2004;52:253-61. (Pubitemid 38146584)
54. Saitou M, Goto M, Horinouchi M, Tamada S, Nagata K, Hamada T, et al. MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas. J Clin Pathol 2005;58:845-52. (Pubitemid 41113392)
55. Haab BB, Porter A, Yue T, Li L, Scheiman J, Anderson MA, et al. Glycosylation variants of mucins and CEACAMs as candidate biomarkers for the diagnosis of pancreatic cystic neoplasms. Ann Surg 2010;251:937-45.
56. Wandall HH, Blixt O, Tarp MA, Pedersen JW, Bennett EP, Mandel U, et al. Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res 2010;70:1306-13.
57. Reis CA, Sorensen T, Mandel U, David L, Mirgorodskaya E, Roepstorff P, et al. Development and characterization of an antibody directed to an alpha-N-acetyl-D-galactosamine glycosylated MUC2 peptide. Glycoconj J 1998;15:51-62. (Pubitemid 28085545)
58. Reis CA, David L, Nielsen PA, Clausen H, Mirgorodskaya K, Roepstorff P, et al. Immunohistochemical study of MUC5AC expression in human gastric carcinomas using a novel monoclonal antibody. Int J Cancer 1997;74:112-21. (Pubitemid 27157865)
59. Nielsen PA, Mandel U, Therkildsen MH, Clausen H. Differential expression of human high-molecular-weight salivary mucin (MG1) and low-molecular-weight salivary mucin (MG2). J Dent Res 1996;75:1820-6. (Pubitemid 32763625)
60. Reis CA, David L, Carvalho F, Mandel U, de Bolos C, Mirgorodskaya E, et al. Immunohistochemical study of the expression of MUC6 mucin and co-expression of other secreted mucins (MUC5AC and MUC2) in human gastric carcinomas. J Histochem Cytochem 2000;48:377-88. (Pubitemid 30131684)
61. Moniaux N, Junker WM, Singh AP, Jones AM, Batra SK. Characterization of human mucin MUC17. Complete coding sequence and organization. J Biol Chem 2006;281:23676-85. (Pubitemid 44274143)
62. Hirohashi S, Clausen H, Yamada T, Shimosato Y, Hakomori S. Blood group A cross-reacting epitope defined by monoclonal antibodies NCC-LU-35 and -81 expressed in cancer of blood group O or B individuals: its identification as Tn antigen. Proc Natl Acad Sci U S A 1985;82:7039-43. (Pubitemid 16209687)
63. Kjeldsen TB, Rasmussen BB, Rose C, Zeuthen J. Human-human hybridomas and human monoclonal antibodies obtained by fusion of lymph node lymphocytes from breast cancer patients. Cancer Res 1988;48:3208-14.
64. Tarp MA, Sorensen AL, Mandel U, Paulsen H, Burchell J, Taylor-Papadimitriou J, et al. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat. Glycobiology 2007;17:197-209. (Pubitemid 46152536)
65. Sorensen AL, Reis CA, Tarp MA, Mandel U, Ramachandran K, Sankaranarayanan V, et al. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology 2006;16:96-107. (Pubitemid 43125966)